CLINICAL_TRIALS
withdrawal
· 2015-07-15
Clinical Trial Update: Topiramate Augmentation in Bulimia Nervosa Partial Responders [Phase 4]
Summary
A Phase 4 clinical trial evaluating topiramate augmentation in partial responders with bulimia nervosa has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota | Conditions: Bulimia Nervosa | Phase 4 | Status: WITHDRAWN